secwatch.observer — SEC 8-K summary
======================================

Issuer:     Hoth Therapeutics, Inc. (HOTH)
CIK:        0001711786
Form:       8-K
Filed at:   2025-08-22T23:59:59+00:00
Accession:  0001213900-25-079915
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Hoth Therapeutics enters new CEO employment agreement with $550k salary and 800k share grant
--------------------------------------------------------------------------------

- CEO Robb Knie's new employment agreement includes $550,000 annual base salary and up to $550,000 annual bonus.
- 800,000 shares of common stock granted to Knie, vesting fully on grant date August 27, 2025.
- Agreement provides for transaction bonus tied to equity value if company engages in license, joint venture, or change of control.
- Company filed PCT patent application for HT-001, a topical treatment for side effects of cancer drugs, claiming priority to two U.S. provisionals.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1711786/000121390025079915/0001213900-25-079915-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1711786/000121390025079915/ea0254112-8k_hoth.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-079915

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer